Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

MODERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Moderna, Inc. on Behalf of Stockholders and Encourages Investors to Contact the Firm

MRNA

NEW YORK

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Moderna, Inc. (NASDAQ: MRNA) on behalf of Moderna stockholders. Our investigation concerns whether Moderna has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

On May 18, 2020, Moderna announced Phase 1 trial results for a candidate vaccine for COVID-19 under development by the Company, indicating that the candidate appeared to generate an immune response similar to the response seen in individuals who have been infected by the virus and recovered. Specifically, Moderna reported that eight patients who received two doses of the vaccine at the lowest and middle doses tested - 25 and 100 micrograms - developed neutralizing antibodies to the virus at levels similar to people who had recovered from infection.

In the days following Moderna’s announcement, the Company’s announcement was the subject of skeptical commentary from multiple sources. For example, on May 19, 2020, STAT published an article entitled “Vaccine experts say Moderna didn’t produce data critical to assessing Covid-19 vaccine,” which noted, in part, that “[w]hile Moderna blitzed the media, it revealed very little information - and most of what it did disclose were words, not data.”

Over the three trading sessions following Moderna’s May 18, 2020 announcement, the Company’s stock price fell $12.95 per share, or 16.19%, to close at $67.05 per share on May 21, 2020.

If you purchased or otherwise acquired Moderna shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato or Marion Passmore by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Bragar Eagel & Squire, P.C.
Melissa Fortunato, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today